The role of istradefylline in the Parkinson’s disease armamentarium

References

• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111(2):201–216.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in Europe: an analysis for the global burden of disease study 2017. Lancet Public Health. 2020;5(10):e551–567. DOI:10.1016/S2468-2667(20)30190-0
   PubMed Web of Science ®Google Scholar
• Müller T. What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease? Expert Opin Pharmacother. 2022;23(7):745–750. DOI:10.1080/14656566.2022.2045275
   PubMed Web of Science ®Google Scholar
• Sivanandy P, Leey TC, Xiang TC, et al. Systematic review on Parkinson’s disease medications, emphasizing on three recently approved drugs to control Parkinson’s symptoms. Int J Environ Res public Health. 2021;19(1):364. Epub. DOI:10.3390/ijerph19010364
   PubMedGoogle Scholar
• Kulkarni A, Preeti K, Tryphena KP, et al. Proteostasis in Parkinson’s disease: recent development and possible implication in diagnosis and therapeutics. Ageing ResRev. 2023;84:101816.
   Google Scholar
• Müller T, Mueller BK, Riederer P. Perspective: treatment for disease modification in chronic neurodegeneration. Cells. 2021;10(4):873. Epub. DOI:10.3390/cells10040873
   PubMed Web of Science ®Google Scholar
• Espay AJ, Okun MS. Abandoning the proteinopathy paradigm in Parkinson disease. JAMA Neurol. 2022;80(2):123. Epub. DOI:10.1001/jamaneurol.2022.4193
   Web of Science ®Google Scholar
• Khot M, Sood A, Tryphena KP, et al. NLRP3 inflammasomes: a potential target to improve mitochondrial biogenesis in Parkinson’s disease. Eur J Pharmacol. 2022;934:175300.
   PubMedGoogle Scholar
• Tryphena KP, Anuradha U, Kumar R, et al. Understanding the involvement of microRNAs in mitochondrial dysfunction and their role as potential biomarkers and therapeutic targets in Parkinson’s disease. J Alzheimers Dis. 2022;1–16. Epub. DOI:10.3233/JAD-220449
   Google Scholar
• Naren P, Cholkar A, Kamble S, et al. Pathological and therapeutic advances in Parkinson’s disease: mitochondria in the interplay. J Alzheimers Dis. 2022;1–30. Epub. DOI:10.3233/JAD-220682
   Google Scholar
• Smolders S, Van BC. Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson’s disease pathogenesis. Acta Neuropathol Commun. 2020;8(1):63.
   PubMed Web of Science ®Google Scholar
• Müller T, Trommer I, Muhlack S, et al. Levodopa increases oxidative stress and repulsive guidance molecule a levels: a pilot study in patients with Parkinson’s disease. J Neural Transm (Vienna). 2016;123(4):401–406. DOI:10.1007/s00702-016-1519-4
   PubMed Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 2012;1(1):1–10.
   PubMedGoogle Scholar
• Fabbrini G, Di SF, Bloise M, et al. Soluble and controlled-release preparations of levodopa: do we really need them? J Neurol. 2010;257(Suppl 2):S292–297. DOI:10.1007/s00415-010-5734-x
   PubMedGoogle Scholar
• Glenardi G, Handayani T, Barus J, et al. Inhaled levodopa (CVT-301) for the treatment of Parkinson disease: a systematic review and meta-analysis of randomized controlled trials. Neurol Clin Pract. 2022;12(2):139–148. DOI:10.1212/CPJ.0000000000001143
   PubMedGoogle Scholar
• LeWitt PA, Stocchi F, Arkadir D, et al. The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: findings from the ND0612 clinical development program. Front Neurol. 2022;13:1036068.
   PubMedGoogle Scholar
• Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099–1109. DOI:10.1016/S1474-4422(22)00400-8
   PubMed Web of Science ®Google Scholar
• Fasano A, Garcia-Ramos R, Gurevich T, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS. J Neurol. 2023. DOI:10.1007/s00415-023-11615-3
   PubMedGoogle Scholar
• Harati A, Müller T. Neuropsychological effects of deep brain stimulation for Parkinson’s disease. Surg Neurol Int. 2013;4(Suppl 6):S443–447.
   PubMedGoogle Scholar
• Klostermann F, Jugel C, Bomelburg M, et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord. 2012;27(13):1704–1705. DOI:10.1002/mds.25238
   PubMed Web of Science ®Google Scholar
• Müller T. GOCOVRI((R)) (amantadine) extended-release capsules in Parkinson’s disease. Neurodegener Dis Manag. 2022;12(1):15–28.
   PubMed Web of Science ®Google Scholar
• Müller T. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease. Expert Opin drug Metab Toxicol. 2017;13(6):693–699.
   PubMed Web of Science ®Google Scholar
• Ferre S, Popoli P, Gimenez-Llort L, et al. Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. Neuroreport. 1994;6(1):73–76. DOI:10.1097/00001756-199412300-00020
   PubMedGoogle Scholar
• Harvey V, Jones J, Misra A, et al. Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors. Eur J Pharmacol. 2001;431(2):171–177. DOI:10.1016/S0014-2999(01)01435-2
   PubMed Web of Science ®Google Scholar
• Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr Neurol Neurosci Rep. 2012;12(4):376–385.
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, et al. Adenosine, adenosine a 2A antagonists, and Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(6):406–413. DOI:10.1016/j.parkreldis.2008.12.006
   PubMed Web of Science ®Google Scholar
• Buira SP, Albasanz JL, Dentesano G, et al. DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. J Neurochem. 2010;112(5):1273–1285. DOI:10.1111/j.1471-4159.2009.06538.x
   PubMedGoogle Scholar
• Bennett KA, Tehan B, Lebon G, et al. Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. Mol Pharmacol. 2013;83(5):949–958. DOI:10.1124/mol.112.084509
   PubMed Web of Science ®Google Scholar
• Collins LE, Galtieri DJ, Collins P, et al. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity. BehavBrain Res. 2010;211(2):148–155. DOI:10.1016/j.bbr.2010.03.003
   Google Scholar
• Perez V, Sosti V, Rubio A, et al. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol. 2007;576(1–3):83–90. DOI:10.1016/j.ejphar.2007.08.024
   PubMed Web of Science ®Google Scholar
• Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 2001;21(10):RC143. DOI:10.1523/JNEUROSCI.21-10-j0001.2001
   PubMed Web of Science ®Google Scholar
• Kartzinel R, Shoulson I, Calne DB. Studies with bromocriptine: iII. concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology. 1976;26(8):741–743.
   PubMed Web of Science ®Google Scholar
• Shoulson I, Chase T. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology. 1975;25(8):722–724.
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord. 2007;22(5):710–712.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651–658. DOI:10.1212/WNL.0b013e318263570d
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18(2):178–184. DOI:10.1016/j.parkreldis.2011.09.023
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233–2240. DOI:10.1212/01.wnl.0000313834.22171.17
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014;13(8):767–776. DOI:10.1016/S1474-4422(14)70148-6
   PubMed Web of Science ®Google Scholar
• Hauser R, Stocchi F, Rascol O, et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson’s disease. Neurology. 2014;82(10 (Supplement)):P7.087.
   Google Scholar
• LeWitt PA, Aradi SD, Hauser RA, et al. The challenge of developing adenosine A(2A) antagonists for Parkinson disease: istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020;80(1):S54–63. DOI:10.1016/j.parkreldis.2020.10.027
   PubMedGoogle Scholar
• Rao N, Dvorchik B, Sussman N, et al. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson’s disease, and atorvastatin. J Clin Pharmacol. 2008;48(9):1092–1098. DOI:10.1177/0091270008320924
   PubMed Web of Science ®Google Scholar
• Rao N. Re: efflux transporter-mediated interactions with atorvastatin–interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. J Clin Pharmacol. 2011;51(5):784.
   PubMedGoogle Scholar
• Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol. 2003;184(1):285–294. DOI:10.1016/S0014-4886(03)00250-4
   PubMed Web of Science ®Google Scholar
• Chen JF, Fredduzzi S, Bastia E, et al. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson’s disease. Neurology. 2003;61(11 Suppl 6):S74–81. DOI:10.1212/01.WNL.0000095218.26363.7B
   PubMedGoogle Scholar
• Grondin R, Bedard PJ, Hadj TA, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52(8):1673–1677. DOI:10.1212/WNL.52.8.1673
   PubMed Web of Science ®Google Scholar
• Kase H, Aoyama S, Ichimura M, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease. Neurology. 2003;61(11 Suppl 6):S97–100. DOI:10.1212/01.WNL.0000095219.22086.31
   PubMedGoogle Scholar
• Orru M, Bakesova J, Brugarolas M, et al. Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One. 2011;6(1):e16088. DOI:10.1371/journal.pone.0016088
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol. 2011;51(1):40–52. DOI:10.1177/0091270010363809
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol. 2012;52(10):1468–1481. DOI:10.1177/0091270011420566
   PubMed Web of Science ®Google Scholar
• Chase TN, Bibbiani F, Bara-Jimenez W, et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology. 2003;61(11 Suppl 6):S107–111. DOI:10.1212/01.WNL.0000095223.08711.48
   PubMedGoogle Scholar
• Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem. 2003;84(6):1398–1410.
   PubMed Web of Science ®Google Scholar
• Lundblad M, Usiello A, Carta M, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005;194(1):66–75. DOI:10.1016/j.expneurol.2005.02.002
   PubMed Web of Science ®Google Scholar
• Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006;26(52):13548–13555. DOI:10.1523/JNEUROSCI.3554-06.2006
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16(1):16–20. DOI:10.1016/j.parkreldis.2009.06.008
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177–2185. DOI:10.1002/mds.22095
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295–302. DOI:10.1002/ana.21315
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437–1443. DOI:10.1002/mds.23107
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28(8):1138–1141.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hattori N, Fernandez H, et al. Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson’s disease: a pooled analysis of 8 phase 2b/3 trials. J Parkinsons Dis. 2021;11(4):1663–1675. DOI:10.3233/JPD-212672
   PubMedGoogle Scholar
• Jenner P, Mori A, Aradi SD, et al. Istradefylline - a first generation adenosine A(2A) antagonist for the treatment of Parkinson’s disease. Expert Rev Neurother. 2021;21(3):317–333. DOI:10.1080/14737175.2021.1880896
   PubMed Web of Science ®Google Scholar
• Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Investig Drugs. 2005;14(6):729–738. DOI:10.1517/13543784.14.6.729
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Saft C, et al. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord. 2000;6(3):171–173. DOI:10.1016/S1353-8020(00)00005-5
   PubMedGoogle Scholar
• Pinna A. Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014;28(5):455–474.
   PubMed Web of Science ®Google Scholar
• Zhu C, Wang G, Li J, et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis. Neurol Res. 2014;36(11):1028–1034. DOI:10.1179/1743132814Y.0000000375
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ito S, Tsuji Y, et al. Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson’s disease: Final report of a post-marketing surveillance study in Japan. J Neurol Sci. 2022;443:120479.
   PubMedGoogle Scholar
• Takahashi M, Shimokawa T, Koh J, et al. Efficacy and safety of istradefylline in patients with Parkinson’s disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan. J Neurol Sci. 2022;432:120078.
   PubMedGoogle Scholar
• Tao Y, Liang G. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson’s disease: a meta-analysis of randomized controlled trials. Cell Biochem Biophys. 2015;71(1):57–62.
   PubMed Web of Science ®Google Scholar
• Yabe I, Kitagawa M, Takahashi I, et al. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease. Clin Neuropharmacol. 2017;40(6):261–263. DOI:10.1097/WNF.0000000000000249
   PubMedGoogle Scholar
• Isobe C, Murata T, Sato C, et al. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer’s disease and Parkinson’s disease. Life Sci. 2005;77(15):1836–1843. DOI:10.1016/j.lfs.2005.02.014
   PubMed Web of Science ®Google Scholar
• Isobe C, Abe T, Terayama Y. Homocysteine may contribute to pathogenesis of RNA damage in brains with Alzheimer’s disease. Neurodegener Dis. 2009;6(5–6):252–257.
   PubMedGoogle Scholar
• Isobe C, Abe T, Terayama Y. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson’s disease. J Clin Neurosci. 2010;17(6):717–721.
   PubMedGoogle Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13(6):707–718.
   PubMed Web of Science ®Google Scholar
• Müller T, Kohlhepp W. Hypomethylation in Parkinson’s disease: An epigenetic drug effect?. Mov Disord. 2016;31(4):605.
   PubMedGoogle Scholar
• Buira SP, Dentesano G, Albasanz JL, et al. DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. J Neurochem. 2010;115(1):283–295. DOI:10.1111/j.1471-4159.2010.06928.x
   PubMedGoogle Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–2508.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–1071. DOI:10.1002/mds.25364
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27. DOI:10.1002/ana.22060
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Goetze O, et al. Entacapone improves absorption of a coadministered salt in patients with Parkinson’s disease. Mov Disord. 2008;23(10):1458–1461. DOI:10.1002/mds.22176
   PubMedGoogle Scholar
• Müller T. Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease. Drugs. 2015;75(2):157–174.
   PubMed Web of Science ®Google Scholar
• Müller T, Schlegel E, Zingler S, et al. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients. Cells. 2022;11(9):1511. DOI:10.3390/cells11091511
   PubMed Web of Science ®Google Scholar
• Russ H, Müller T, Woitalla D, et al. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol. 1999;360(6):719–720. DOI:10.1007/s002109900168
   PubMed Web of Science ®Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6(2):141–150. DOI:10.1111/j.1468-1331.1999.tb00007.x
   PubMed Web of Science ®Google Scholar
• Müller T, Laar van LT, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013;19(5):501–507. DOI:10.1016/j.parkreldis.2013.02.006
   PubMed Web of Science ®Google Scholar
• Jugel C, Ehlen F, Taskin B, et al. Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One. 2013;8(6):e66639. DOI:10.1371/journal.pone.0066639
   PubMed Web of Science ®Google Scholar
• Morley JF, Duda JE. Parkinson’s disease and the risk of cerebrovascular pathology. Mov Disord. 2012;27(12):1471–1472.
   PubMed Web of Science ®Google Scholar
• Rektor I, Goldemund D, Bednarik P, et al. Impairment of brain vessels may contribute to mortality in patients with Parkinson’s disease. Mov Disord. 2012;27(9):1169–1172. DOI:10.1002/mds.25066
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Halliday GM, Cordato DJ, et al. Small-vessel disease in patients with Parkinson’s disease: a clinicopathological study. Mov Disord. 2012;27(12):1506–1512. DOI:10.1002/mds.25112
   PubMed Web of Science ®Google Scholar
• Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–1205. DOI:10.1016/S0140-6736(14)60683-8
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297–303.
   PubMed Web of Science ®Google Scholar